Articles

New rules raise stakes for Lilly drug

Drugmakers testing experimental Alzheimer’s medicines—including Eli Lilly and Co.—got good news last week
when the National Institute on Aging and the Alzheimer’s Association proposed new guidelines to make earlier diagnoses
of the disease.

Read More

Lilly’s Alzheimer’s gamble takes aim at $10 billion in patent losses

Both of Lilly’s late-stage treatments are designed to reduce plaque in the brain called beta amyloid, thought by researchers
to be a main contributor to Alzheimer’s. A drug that stops or reduces memory loss caused by Alzheimer’s may be worth more
than $5 billion
a year, an analyst says, helping Lilly overcome the coming patent losses on several important pharmaceuticals.

Read More

Lilly hopes Elanco unit becomes a cash cow

Elanco Animal Health chief Jeff Simmons predicts that consumers will opt for food made cheaper by using
Elanco’s productivity-enhancing drugs over pricier organic and locally grown products. But, as a hedge,
he has Elanco developing products to help organic farmers, too.

Read More

Chao exit hurts drug development industry

Purdue University’s decision to close the Chao Center in West Lafayette is a setback for Indiana’s effort to grow
a vibrant contract drug manufacturing sector. But it’s just the latest in a series of unexpected changes—not all for
the worse—since Indianapolis-based BioCrossroads launched a contract drug manufacturing initiative in late 2007.

Read More